TXG — 10X Genomics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.33bn
- $2.94bn
- $618.73m
- 61
- 19
- 53
- 40
Annual cashflow statement for 10X Genomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -31.3 | -543 | -58.2 | -166 | -255 |
| Depreciation | |||||
| Non-Cash Items | 14 | 361 | 103 | 146 | 187 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 44.8 | -50.4 | -87.4 | -39.4 | 17.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 34.6 | -218 | -21.4 | -33.6 | -15.2 |
| Capital Expenditures | -42.8 | -38.4 | -101 | -132 | -49.5 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | -5.45 | -219 | 183 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -42.8 | -38.4 | -107 | -351 | 133 |
| Financing Cash Flow Items | — | -5.85 | -5.03 | -5.41 | -5.81 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 415 | 469 | 35.3 | 15.8 | 13.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 406 | 212 | -92.6 | -369 | 132 |